As people with lupus have become increasingly educated about their disease and involved in their medical care, input from patients about their condition has become increasingly important and useful. Recently, the Lupus Damage Index Questionnaire (LDIQ) was developed for this purpose and captures the spectrum of knowledge acquired from the SDI in a patient-reported questionnaire.
For years, researchers have investigated the possibility of inhibiting the actions of lupus-related autoantibodies to reduce the extent of organ damage. Further research in this area has the potential to facilitate the development of new therapies for people with lupus.
Since lupus nephritis can be severe and the therapy can be toxic, it is important to be able to predict which patients would most benefit from long-term treatment.
The researchers hoped to learn whether people with lupus kidney involvement from different races shared the same set of microRNAs.
Current treatments for lupus nephritis in children are toxic and sometimes ineffective. New tests for proteins that might be abnormal in lupus nephritis could help make the diagnosis earlier and might also point to new ways of treating the disease.
Epratuzumab is an investigational agent for the treatment of lupus. The researchers hoped to learn whether epratuzumab could be a safe and effective treatment for people with moderate-to-severe lupus.
There are a number of treatments used for lupus nephritis, but none of them are approved by the U.S. Food and Drug Administration (FDA). The researchers hoped to compare the efficacy and safety of MMF and azathioprine as maintenance therapy.
The researchers hoped to learn whether treatment with belimumab could reduce the use of steroids in people with active lupus.